中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | (E)-3-(pyridin-2-yl ethynyl)cyclohex-2-enone O-(3-(2-[18F]-fluoroethoxy)propyl)oxime | 1451015-40-9 | C18H21FN2O2 | 315.377 |
—— | (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone O-(3-(2-fluoroethoxy)propyl) oxime | 1451015-37-4 | C18H21FN2O2 | 316.375 |
—— | (E)-2-[3-[[[3-(2-Pyridylethynyl)-2-cyclohexen-1-ylidene]amino]oxy]propoxy]ethyl Methanesulfonate | —— | C19H24N2O5S | 392.476 |
—— | (E)-2-(3-(((3-(pyridin-2-ylethynyl)cyclohex-2-en-1-ylidene)amino)oxy)propoxy)ethylmethanesulfonate | 1451015-35-2 | C19H24N2O5S | 392.476 |
Involvement of metabotropic glutamate receptor subtype 5 (mGluR5) in physiological and pathophysiological processes in the brain has been demonstrated, and hence mGluR5 has emerged as an important drug target. [11C]-ABP688 is clinically the most successful mGluR5 positron emission tomography (PET) tracer to date and it allows visualization and quantification of mGluR5. Due to the short half-life of carbon-11, clinical use of [11C]-ABP688 is limited to facilities with an on-site cyclotron and a fluorine-18 (half-life 110 min) analogue would be more practical. Based on the [11C]-ABP688 structural motif, a novel derivative [18F]-PSS223 was prepared and evaluated as a PET tracer for imaging of mGluR5 in vitro and in vivo. Our results show favourable in vitro binding properties; however rapid defluorination of [18F]-PSS223 does not allow visualization of mGluR5 in the rat brain.